The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Encouraging GEM-CESAR update: curative strategy for high-risk smoldering myeloma
Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, discusses the latest results from the GEM-CESAR trial (NCT02415413) of a curative treatment strategy for high-risk smoldering myeloma. This phase II trial consists of induction with carfilzomib, lenalidomide and dexamethasone (KRd), followed by HDT-ASCT, consolidation with KRd and maintenance with Rd. Dr Mateos mentions a planned amendment to this trial and highlights the importance of early detection and early intervention in smoldering myeloma. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
